[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-exacerbation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-exacerbation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,83,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100605778","phase-4-45th-multicenter-airway-research-collaboration-100605778",false,"NCT07166939","45th Multicenter Airway Research Collaboration","A Phase 4, Multicenter, Cluster Randomized, Open-label, Intervention Versus Usual Care, Controlled Study on the Effect of Emergency Department Initiation of Airsupra on Asthma Outcomes","MARC-45","INCLUSION CRITERIA:\n\n* acute asthma\n* age 18.0 to 54.9 years\n* English and\u002For Spanish speaking\n* decision by ED attending to discharge patient to home on short course of systemic corticosteroids\n* (intervention group only) Willingness to use Airsupra as their rescue inhaler for next 3 months\n* demonstration of acceptable MDI administration technique\n* provision of informed consent prior to any study-specific procedures\n\nEXCLUSION CRITERIA:\n\n* involvement in the planning and\u002For conduct of the study\n* previous enrolment in the present study\n* prior diagnosis of COPD, chronic bronchitis, or emphysema\n* use of systemic corticosteroids in the past 2 weeks\n* participation in another clinical study with an investigational product during the past 4 weeks or the 3 months after enrollment in the current study\n* concurrent pneumonia\n* clinically significant cardiovascular disease or clinically significant cancer\n* patients with known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any of the excipients of the product\n* (for women only, by self-report):\n* currently pregnant\n* currently breastfeeding,\n* (among sexually active women of child-bearing age only) not using adequate contraception over the last 3 months, or no plan to use adequate contraception over the next 3 months\n* lack of a working cell phone and working email address\n* expected lack of availability for text and\u002For telephone follow-up at approximately 3, 6, and 12 weeks after the ED visit\n* inability to provide an alternate contact with a working cell phone and working email address.","ALL","18 Years","54 Years",{"count":21,"type":22},1860,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma \"recurrence\" at 3 months and other related outcomes (acute asthma relapse, asthma control).",[28,29,30,31],"Asthma Acute","Asthma Exacerbation","Asthma","Asthma Control Level",[33,34,35,36,37,38,39,40,41],"asthma","emergency department","airsupra","randomized trial","acute asthma recurrence","acute asthma relapse","asthma control","acute asthma","asthma exacerbation","RECRUITING","2026-04-14",{"date":45,"type":46},"2026-04-17","ACTUAL",{"date":48,"type":46},"2025-11-07",{"date":50,"type":22},"2027-06",{"name":52,"class":53},"Massachusetts General Hospital","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":54},"100631427","evaluation-of-the-medentum-diagnostik-platform-for-pediatric-ent-conditions-and-asthma-100631427","NCT07500532","Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma","Inclusion Criteria:\n\n* Age: Patients between the ages of 4 and 17 years (asthma) and 3-17 years (ENT)\n* Diagnosis:\n\n  o Asthma patients: Diagnosed with mild-to-moderate and severe persistent asthma according to Global Initiative for Asthma (GINA) guidelines, with a history of symptoms or exacerbations requiring medical intervention (prior prednisone course and\u002For albuterol for \\>24 hours in context of acute wheezing episode) in the past 12 months. ENT patients: Diagnosed with common ENT conditions such as acute otitis media (AOM) or strep pharyngitis in the prior year. Diagnosis must be based on established clinical guidelines.\n* Technology access: Must have access to a smartphone, tablet, or other device capable of running the Medentum Diagnostik platform app and access to Wifi or cellular service.\n* Care access: Must be receiving routine care from University of Arizona or associated clinics in Arizona and have active health insurance\n* Consent: Must have parental or guardian consent for participation, as well as child assent when appropriate.(all children ≥7 yrs)\n\nExclusion Criteria:\n\n* Other medical conditions: Patients with additional chronic lung diseases (such as cystic fibrosis) requiring complex specialist care will be excluded. cerebral palsy, neurodevelopmental conditions, congenital heart disease. Patients with complex chronic conditions or chronic ENT conditions requiring complex specialist care will be excluded.\n* Recent surgical\u002Fcomplex ENT medical history: Patients who have had tympanostomy tubes or tonsillectomy\u002Fadenoidectomy, patients with chronic ENT conditions including chronic suppurative or serous otitis media\n* Recent medical history: Patients who have experienced severe asthma exacerbations requiring hospitalization or intensive treatment in the past 4 weeks\n* Comorbidities: Patients with speech delays, hearing impairments, or cognitive impairments that may affect their ability to use the Diagnostik platform accurately will be excluded.\n* Non-compliance risk: Patients or families that are unable to follow study instructions, comply with follow-up visits, or properly use the Medentum platform will be excluded.",true,"3 Years","17 Years",{"count":65,"type":22},84,[67],"NA","This study evaluates the diagnostic performance, usability, and clinical utility of the Medentum Diagnostik platform, a multisensor device with integrated software and artificial intelligence, in pediatric patients with asthma and ENT conditions. Participants will be assigned to either home-based use of the Diagnostik platform with telehealth-supported clinician evaluation or standard in-person care.\n\nThe primary objective is to assess agreement between AI-generated diagnoses and clinician diagnoses obtained during study encounters, including telehealth evaluations in the Diagnostik arm and in-person evaluations in the standard-of-care arm. Secondary objectives include evaluating agreement between AI-generated diagnoses and independent research team diagnoses, as well as assessing usability, patient and caregiver satisfaction, healthcare utilization, and clinical outcomes such as asthma control and symptom resolution.\n\nThis study will also evaluate differences in healthcare utilization, including in-person visits, emergency care use, and time to diagnosis and treatment, between study groups.",[70,71,29,72],"Acute Otitis Media (AOM)","Strep Pharyngitis","Pediatric Asthma","2026-03-25",{"date":75,"type":46},"2026-03-30",{"date":77,"type":46},"2025-10-01",{"date":79,"type":22},"2026-12-01",{"name":81,"class":82},"Medentum Innovations","INDUSTRY",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100630532","phase-1-rig-101-trial-in-healthy-adults-and-adults-with-asthma-100630532","NCT07488897","RIG 101 Trial in Healthy Adults and Adults With Asthma","A Two-part Randomized, Double-blind Placebo Controlled Trial to Assess the Safety and Tolerability of Single and Repeat Ascending Intranasal Doses of RIG-101 in Healthy Participants Followed by Repeat Daily Administration in Adult Participants With Asthma [Part A] Followed by a Randomized Double-blind Placebo Controlled Part to Assess the Efficacy and Safety of RIG-101 in Adult Participants With Asthma Before and After Viral Challenge With Human Rhinovirus RV-A16 [Part B].","Inclusion Criteria:\n\nParticipants must meet all the following inclusion criteria to be eligible to participate in the trial.\n\n* Participants must have a written informed consent obtained prior to any trial related procedure\n* Male and female participants aged between 18 to 65 years inclusive, at the time of informed consent.\n* Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory assessments at the time of screening, as judged by the Investigator.\n\nAdditional Inclusion Criteria for Healthy Participants\n\n\\- Participants must have a pre-bronchodilator FEV1 ≥80% predicted (using GLI Global predicted values17) and an FEV1 \u002F FVC ratio of \\>70% absolute at screening.\n\nAdditional Inclusion Criteria for Participants with Asthma\n\n* Participants must have a clinical diagnosis of asthma.\n* Participants must have either a positive skin prick test with a wheal diameter of ≥3mm greater than control test at 15 minutes, and\u002For a blood eosinophil count of \\> 200 cells \u002F µL and\u002For a FeNO level of \\> 25 ppb at screening.\n* Participants must have a pre-bronchodilator FEV1 ≥65% predicted at screening\n* Participants must be using SABA alone or inhaled corticosteroids (ICS) with SABA or ICS with formoterol as reliever therapy, AND\u002FOR regular use of low to mid-dose ICS with or without LABA at a stable dose for at least 3 months prior to randomization to control their asthma.\n\nPart B only\n\n* Participants must have an ACQ-6 score of \\> 0.75 at screening.\n* Participants must have a history of asthma worsening in the previous 2 years, in response to a cold or respiratory infection, as confirmed by the participant.\n* Participants must demonstrate seronegativity to RV-A16\n\nExclusion Criteria:\n\nExclusion Criteria for all Participants\n\n* History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical trial, expose the participant to undue risk or interfere with the participants ability to successfully conduct the trial, as judged by the Investigator.\n* Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the trial at time of screening.\n* Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first administration of IMP and\u002For history of being hospitalized due to epistaxis on any previous occasion.\n* Any nasal or sinus surgery within 3 months of the first administration of IMP\n* Any signs of upper respiratory tract infection within 6 weeks of screening or prior to first administration of IMP\n* Current or previous use of tobacco, nicotine products or e-cigarettes in the past 6 months prior to screening.\n* Smoking history of \\> 5 pack years.\n\nAdditional Exclusion Criteria for Participants with Asthma\n\n* Any asthma exacerbation on their current asthma controller medication requiring oral\u002Fsystemic corticosteroids within 8 weeks of randomization, or that resulted in overnight hospitalization requiring additional treatment for asthma within 3 months of randomization.\n* Difficult-to-treat or severe asthma requiring the maintenance use of add-on biologic Type 2 targeted treatments including anti-Immunoglobulin E, anti-IL4 receptor, anti-IL5, anti-IL5 receptor, and anti-Thymic Stromal Lymphopoietin\n* History of life-threatening asthma, defined as any asthma episode that required admission to a high-dependency or intensive therapy unit.\n* Individuals with close contact to at risk patient groups","65 Years",{"count":92,"type":22},82,[94,95],"PHASE1","PHASE2","Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy",[98,29,99],"Healthy Adult Participants","Safety and Efficacy","2026-03-18",{"date":102,"type":46},"2026-03-23",{"date":104,"type":46},"2026-02-09",{"date":106,"type":22},"2027-02",{"name":108,"class":82},"RIGImmune Inc.",2,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":117,"maxAge":63,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":134,"leadSponsor":136,"locationsCount":54},"100613041","pollution-intervention-to-impact-kids-asthma-study-100613041","NCT07261423","Pollution Intervention to Impact Kids Asthma Study","PIKAS","Inclusion Criteria:\n\n* A healthcare provider diagnosis of persistent asthma (Steps 2-5 as defined by US guidelines) or intermittent asthma (Step 1) + at least one severe asthma exacerbation (defined by American Thoracic Society (ATS)\u002FEuropean Respiratory Society (ERS) criteria as requiring at least 3 days of systemic steroids or an Emergency Department\u002FUrgent Care visit requiring systemic steroids) in the prior 12 months\n* Home access to a smartphone or internet\n* Primary residence in Allegheny County, PA\n* One participant per household\n* Age 8 -17 years\n* Healthcare provider evaluation for asthma in the prior year\n\nExclusion Criteria:\n\n* Diagnosis of other active chronic respiratory diseases (e.g., cystic fibrosis, bronchopulmonary dysplasia, etc.)\n* Neuromuscular disorder\n* Chronic disorder limiting independent ambulation (e.g., spastic quadriplegia, etc.)\n* Cyanotic heart disease\n* Plans to relocate from Allegheny County, PA in the next year (12 months)\n* Use of intranasal or oral\u002Fintramuscular\u002Fintravenous corticosteroids 4 weeks prior to randomization\n* Current participation in another asthma intervention trial","8 Years",{"count":119,"type":22},351,[67],"The goal of this clinical trial is to learn if adding Air Quality Index (AQI) information to asthma action plans works to improve asthma outcomes in children. It will also learn about children with asthma who report being more sensitive to outdoor air pollution. The main questions it aims to answer are:\n\n* Does adding either information about the EPA-AQI or commercial AQI improve asthma outcomes over time?\n* Are there changes in nasal gene expression in children with asthma who report they are more sensitive to outdoor air pollution?\n\nResearchers will compare EPA-AQI and the commercial-AQI groups to a control group to either AQI works to improve asthma.\n\nParticipants will:\n\n* Receive standardized outdoor air pollution education and an asthma action plan\n* Provide nose and blood specimens\n* Have visits every 4 weeks for 48 weeks, 10 will be conducted by telephone calls and 3 visits will be in person.",[123,124,29,125],"Childhood Asthma","Asthma Control","Air Pollution, Risk Reduction Behaviors",[127,128,129],"childhood asthma","air quality index","AQI","2026-02-24",{"date":132,"type":46},"2026-02-27",{"date":130,"type":46},{"date":135,"type":22},"2030-01",{"name":137,"class":53},"University of Pittsburgh"]